Tandem Diabetes Care, Inc.TNDM stock score: 38/100
$16.80 · -1.47% · Scored Nov 19, 2026
- Technical
- 30
- Fundamental
- 41
- News
- 60
The reading
Tandem Diabetes Care (TNDM) scores 38 out of 100, which reads bearish, higher than 20% of Healthcare stocks and 19% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 41, technicals 30.
Among the fundamentals, Price Target at 100 and Current Ratio at 96 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 29 and contrarian oscillators 59 — a split worth reading before trusting the technical total.
News sentiment is positive at 60; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 32 to 44, and it is down 6 points over the period.
About Tandem Diabetes Care
Tandem Diabetes Care (TNDM) makes insulin pumps and related supplies for people with diabetes. Its products include the t:slim X2 insulin pump and the Tandem Mobi, a smaller pump that can be controlled from a smartphone app. Both use Tandem’s automated insulin delivery software, which works with continuous glucose monitors from partners such as Dexcom and Abbott to adjust insulin doses based on glucose readings. The company is developing a tubeless version of Mobi and a next-generation patch pump known as Sigi. Its pumps serve people with type 1 and type 2 diabetes in the United States and, mainly through distributors, abroad. Tandem earns money from the sale of pumps and from recurring sales of cartridges, infusion sets and other supplies, which are shifting from durable medical equipment coverage toward pharmacy benefits under a pay-as-you-go model.
Tandem competes with Insulet, maker of the Omnipod patch pump, Medtronic’s MiniMed diabetes business and Beta Bionics. Its edge rests on automated insulin delivery software that is well regarded by clinicians, integration with multiple glucose monitors and a growing installed base that buys supplies over time. Investors who follow TNDM stock tend to watch pump shipments and new patient starts in the United States and abroad. Progress in shifting to the pharmacy channel and the timing of new products are closely followed. Gross margins, operating expenses, reimbursement and cash use are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward TNDM’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
41Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Asset turnover is revenue divided by total assets: how much sales a company generates from each dollar of assets.
Holding it back
5-year earnings growth evaluates long-term profit trajectory and consistency.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Share of the float sold short.
39 weighted scorers.
Technical · daily
31Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Williams %R (7-period) places the close within the last 7 periods' high-low range.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Where the close sits against its 20-day SMA.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 60
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 34 | 1 |
| Daily | 31 | 3 |
| Weekly | 25 | 2 |
| Monthly | 31 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 38 |
| Nov 18, 2026 | 39 |
| Nov 17, 2026 | 39 |
| Nov 16, 2026 | 42 |
| Nov 15, 2026 | 43 |
| Nov 14, 2026 | 43 |
| Nov 13, 2026 | 43 |
| Nov 12, 2026 | 39 |
| Nov 11, 2026 | 41 |
| Nov 10, 2026 | 40 |
| Nov 8, 2026 | 33 |
| Nov 7, 2026 | 33 |
| Nov 6, 2026 | 32 |
| Nov 5, 2026 | 41 |
| Nov 4, 2026 | 41 |
| Nov 3, 2026 | 38 |
| Nov 2, 2026 | 41 |
| Nov 1, 2026 | 41 |
| Oct 31, 2026 | 42 |
| Oct 30, 2026 | 42 |
| Oct 29, 2026 | 43 |
| Oct 28, 2026 | 43 |
| Oct 27, 2026 | 43 |
| Oct 26, 2026 | 41 |
| Oct 25, 2026 | 38 |
| Oct 24, 2026 | 38 |
| Oct 23, 2026 | 38 |
| Oct 22, 2026 | 37 |
| Oct 21, 2026 | 35 |
| Oct 20, 2026 | 36 |
| Oct 19, 2026 | 35 |
| Oct 18, 2026 | 35 |
| Oct 17, 2026 | 35 |
| Oct 16, 2026 | 35 |
| Oct 15, 2026 | 35 |
| Oct 14, 2026 | 35 |
| Oct 13, 2026 | 36 |
| Oct 12, 2026 | 36 |
| Oct 11, 2026 | 35 |
| Oct 10, 2026 | 35 |
| Oct 9, 2026 | 35 |
| Oct 8, 2026 | 33 |
| Oct 7, 2026 | 34 |
| Oct 6, 2026 | 34 |
| Oct 5, 2026 | 35 |
| Oct 4, 2026 | 36 |
| Oct 3, 2026 | 36 |
| Oct 2, 2026 | 36 |
| Oct 1, 2026 | 35 |
| Sep 30, 2026 | 35 |
| Sep 29, 2026 | 36 |
| Sep 28, 2026 | 36 |
| Sep 27, 2026 | 35 |
| Sep 26, 2026 | 35 |
| Sep 25, 2026 | 34 |
| Sep 24, 2026 | 34 |
| Sep 23, 2026 | 35 |
| Sep 22, 2026 | 36 |
| Sep 21, 2026 | 36 |
| Sep 20, 2026 | 34 |
| Sep 19, 2026 | 34 |
| Sep 18, 2026 | 34 |
| Sep 17, 2026 | 35 |
| Sep 16, 2026 | 35 |
| Sep 15, 2026 | 33 |
| Sep 14, 2026 | 35 |
| Sep 13, 2026 | 35 |
| Sep 12, 2026 | 35 |
| Sep 11, 2026 | 35 |
| Sep 10, 2026 | 36 |
| Sep 9, 2026 | 38 |
| Sep 8, 2026 | 41 |
| Sep 7, 2026 | 41 |
| Sep 6, 2026 | 40 |
| Sep 5, 2026 | 40 |
| Sep 4, 2026 | 41 |
| Sep 3, 2026 | 43 |
| Sep 2, 2026 | 43 |
| Sep 1, 2026 | 44 |
| Aug 31, 2026 | 44 |
| Aug 30, 2026 | 42 |
| Aug 29, 2026 | 42 |
| Aug 28, 2026 | 43 |
| Aug 27, 2026 | 42 |
| Aug 26, 2026 | 42 |
| Aug 25, 2026 | 43 |
| Aug 24, 2026 | 44 |
| Aug 23, 2026 | 44 |
| Aug 22, 2026 | 44 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 1.59
- Risk grade (1–10)
- 3
- Next earnings
- Nov 5, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| NVCR NovoCure | $1.2B | 44 |
| SIBN SI-BONE | $1.1B | 59 |
| ATEC Alphatec | $1.1B | 52 |
| IART Integra LifeSciences Holdings | $1.1B | 43 |
| IRMD IRADIMED | $1.0B | 66 |
| CBLL CeriBell | $1.0B | 51 |
Questions
What is TNDM's stock rating today?
TNDM scores 38/100 (Bearish) as of Nov 19, 2026: technical 30, fundamental 41, and news sentiment 60, which is shown but not counted. Scores are recomputed every night.
What does Tandem Diabetes Care do?
Tandem Diabetes Care (TNDM) makes insulin pumps and related supplies for people with diabetes. Its products include the t:slim X2 insulin pump and the Tandem Mobi, a smaller pump that can be controlled from a smartphone app.
Is TNDM stock a buy?
The score is not a buy or sell recommendation. A 38 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the TNDM score calculated?
101 weighted scorers feed it today: 39 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/tndm/"><img src="https://stocksscores.com/stocks/tndm/badge.svg" alt="TNDM stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/tndm/)